small molecule

WEGOVY FLEXTOUCH

SEMAGLUTIDE

Loss of exclusivityMay 2040latest FDA-listed patent expiry

CompanyNOVO NORDISK INC

Drug detail

Brand name	WEGOVY FLEXTOUCH
Active ingredient	SEMAGLUTIDE
Strength	9.6MG/3ML (3.2MG/ML)
Dosage form	SOLUTION
Route	SUBCUTANEOUS
Modality	Small molecule
FDA approval	June 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
11478533	May 2040	use U-3861
12551536	October 2038	use U-4418
12029779	October 2038	use U-3162
9764003	June 2033	use U-3161
8129343	December 2031	substance, product

Regulatory exclusivity

Code	Expires
I-973	August 2028
I-935	March 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from NOVO NORDISK INC